|
1
|
El-Serag Hb: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lyra-González I, Flores-Fong LE,
González-García I, Medina-Preciado D and Armendáriz-Borunda J:
MicroRNAs dysregulation in hepatocellular carcinoma: Insights in
genomic medicine. World J Hepatol. 7:1530–1540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu Z, Zhang X, Wang G and Zheng H: Role
of MicroRNAs in hepatocellular carcinoma. Hepat Mon. 14:e186722014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chung V: Systemic therapy for
hepatocellular carcinoma and cholangiocarcinoma. Surg Oncol Clin N
Am. 24:187–198. 2015. View Article : Google Scholar
|
|
5
|
Yang F, Teves SS, Kemp CJ and Henikoff S:
Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys
Acta. 1845:84–89. 2014.
|
|
6
|
Marczak A, Denel-Bobrowska M, Rogalska A,
Łukawska M and Oszczapowicz I: Cytotoxicity and induction of
apoptosis by formamidinodoxorubicins in comparison to doxorubicin
in human ovarian adenocarcinoma cells. Environ Toxicol Pharmacol.
39:369–383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu F, Wang F, Yang T, Sheng Y, Zhong T and
Chen Y: Differential drug resistance acquisition to doxorubicin and
paclitaxel in breast cancer cells. Cancer Cell Int. 14:5382014.
View Article : Google Scholar
|
|
8
|
Teply BA and Kim JJ: Systemic therapy for
bladder cancer-a medical oncologist's perspective. J Solid Tumors.
4:25–35. 2014. View Article : Google Scholar :
|
|
9
|
Zhao X, Chen Q, Liu W, Li Y, Tang H, Liu X
and Yang X: Codelivery of doxorubicin and curcumin with lipid
nanoparticles results in improved efficacy of chemotherapy in liver
cancer. Int J Nanomedicine. 10:257–270. 2014.
|
|
10
|
Shuhendler AJ, Prasad P, Zhang RX, Amini
MA, Sun M, Liu PP, Bristow RG, Rauth AM and Wu XY: Synergistic
nanoparticulate drug combination overcomes multidrug resistance,
increases efficacy and reduces cardiotoxicity in a
nonimmunocompromised breast tumor model. Mol Pharm. 11:2659–2674.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohtsuka M, Ling H, Doki Y, Mori M and
Calin GA: MicroRNA processing and human cancer. J Clin Med.
4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Donzelli S, Mori F, Biagioni F, Bellissimo
T, Pulito C, Muti P, Strano S and Blandino G: MicroRNAs: Short
non-coding players in cancer chemoresistance. Mol Cell Ther.
2:162014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: MicroRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian H, Hou L, Xiong YM, Huang JX, She YJ,
Bi XB and Song XR: MiR-218 suppresses tumor growth and enhances the
chemosensitivity of esophageal squamous cell carcinoma to
cisplatin. Oncol Rep. 33:981–989. 2015.
|
|
15
|
Zeng Q, Jin C, Chen W, Xia F, Wang Q, Fan
F, Du J, Guo Y, Lin C, Yang K, et al: Downregulation of serum
miR-17 and miR-106b levels in gastric cancer and benign gastric
diseases. Chin J Cancer Res. 26:711–716. 2014.
|
|
16
|
Shen Q, Bae HJ, Eun JW, et al: MiR-101
functions as a tumor suppressor by directly targeting nemo-like
kinase in liver cancer. Cancer Lett. 344:204–211. 2014. View Article : Google Scholar
|
|
17
|
Lv P, Zhang P, Li X and Chen Y: Micro
ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion
of lung cancer by regulating cyclooxygenase-2. Thorac Cancer.
6:778–784. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li JT, Jia LT, Liu NN, Zhu XS, Liu QQ,
Wang XL, Yu F, Liu YL, Yang AG and Gao CF: MiRNA-101 inhibits
breast cancer growth and metastasis by targeting CX chemokine
receptor 7. Oncotarget. 6:30818–30830. 2015.PubMed/NCBI
|
|
19
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Tong SJ, Liu J, Wang X and Qu LX:
MicroRNA-181 promotes prostate cancer cell proliferation by
regulating DAX-1 expression. Exp Ther Med. 8:1296–1300.
2014.PubMed/NCBI
|
|
22
|
Misra R, Das M, Sahoo BS and Sahoo SK:
Reversal of multidrug resistance in vitro by co-delivery of MDR1
targeting siRNA and doxorubicin using a novel cationic poly
(lactide-co-glycolide) nanoformulation. Int J Pharm. 475:372–384.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takasaki S: Roles of microRNAs in cancers
and development. Methods Mol Biol. 1218:375–413. 2015. View Article : Google Scholar
|
|
24
|
Hu Z, Lin Y, Chen H, Mao Y, Wu J, Zhu Y,
Xu X, Xu X, Li S, Zheng X and Xie L: MicroRNA-101 suppresses
motility of bladder cancer cells by targeting c-Met. Biochem
Biophys Res Commun. 435:82–87. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chiang CW, Huang Y, Leong KW, Chen LC,
Chen HC, Chen SJ and Chou CK: PKCalpha mediated induction of
miR-101 in human hepatoma HepG2 cells. J Biomed Sci. 17:352010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu
C, Zou L, Li Z, Zhao J and Lin N: MicroRNA-101 suppresses
SOX9-dependent tumorigenicity and promotes favorable prognosis of
human hepatocellular carcinoma. FEBS Lett. 586:4362–4370. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang HJ, Ruan HJ, He XJ, et al:
MicroRNA-101 is downregulated in gastric cancer and involved in
cell migration and invasion. Eur J Cancer. 46:2295–2303. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Quinn BA, Dash R, Azab B, et al: Targeting
Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs.
20:1397–1411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun JG, Xiang J, Zeng XL, Li X, Wu P, Fung
KP and Liu FY: Clitocine induces apoptosis and enhances the
lethality of ABT-737 in human colon cancer cells by disrupting the
interaction of Mcl-1 and Bak. Cancer Lett. 355:253–263. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao
Y, Lv Y and Song Y: MiR-101 and Mcl-1 in nonsmall-cell lung cancer:
Expression profile and clinical significance. Med Oncol.
29:1681–1686. 2012. View Article : Google Scholar
|
|
31
|
Zhang T, Zhao C, Luo L, Zhao H, Cheng J
and Xu F: The expression of Mcl-1 in human cervical cancer and its
clinical significance. Med Oncol. 29:1985–1991. 2012. View Article : Google Scholar
|
|
32
|
Doi K, Gowda K, Liu Q, Lin JM, Sung SS,
Dower C, Claxton D, Loughran TP Jr, Amin S and Wang HG: Pyoluteorin
derivatives induce Mcl-1 degradation and apoptosis in hematological
cancer cells. Cancer Biol Ther. 15:1688–1699. 2014. View Article : Google Scholar : PubMed/NCBI
|
